Bone loss associated with depot medroxyprogesterone acetate was reversible in a prospective population-based cohort study.
In 183 nonpregnant, reproductive-age users of the injectable contraceptive, which is sold as Depo-Provera, bone density at the spine changed at an annualized mean rate of -0.87%, compared with 0.40% in 274 nonusers. Bone density at the hip changed by -1.12% in users, compared with -0.05% in nonusers, reported. Delia Scholes, Ph.D., and her colleagues at the University of Washington, Seattle.
But in 110 of the Depo-Provera users who discontinued the agent, sizable increases in bone density were noted. The estimated annualized mean change at the spine was 1.41% in those who stopped using Depo-Provera, compared with 1.03 in those who continued using it. At the hip, the estimated change was 0.40% in those who stopped use, compared with -0.05% in those who continued. At 30 months follow-up, bone density in those who stopped using Depo-Provera was similar to that of the control patients who had not used it (Epidemiology 13[5]:581-87, 2002).
COPYRIGHT 2002 International Medical News Group
COPYRIGHT 2002 Gale Group